The LEADER trial (liraglutide) reported pancreatitis in 0.3% of liraglutide patients versus 0.1% of placebo patients over a median 3.8 years
The test identifies your genetic variants in GIPR, FTO, and MC4R, and 45 other peptide-pathway genes, mapping 14 metabolic systems and revealing your predisposition to GLP-1 sensitivity, GIP pathway activation, and energy expenditure patterns
It is not a dietary supplement, medication, or food product and is not intended for human consumption
The Benefits Beyond Weight Loss Weight loss is the most searched outcome, but the published trial data extends considerably further
Instead of worrying whether your peptides are still effective or wasting money discarding good peptides too early, you get personalized protocols with clear timelines, storage guidance, and expert AI support whenever questions arise
Pre-and post-exercise nutrition Exercise, particularly resistance training, is strongly recommended during semaglutide use for muscle preservation